Your browser doesn't support javascript.
Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience.
Ramamurthy, Lakshmi B; Bhandari, Ridhi; Kanakpur, Savitha; Thejaswini, P.
  • Ramamurthy LB; Department of Ophthalmology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India.
  • Bhandari R; Department of Ophthalmology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India.
  • Kanakpur S; Department of Ophthalmology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India.
  • Thejaswini P; Department of Ophthalmology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India.
Indian J Ophthalmol ; 70(3): 1019-1024, 2022 03.
Article in English | MEDLINE | ID: covidwho-1715917
ABSTRACT

Purpose:

To assess the outcome and response of transcutaneous retrobulbar injection of amphotericin B (TRAMB) in post-coronavirus disease of 2019 (COVID-19) rhino-orbito-cerebral mucormycosis (ROCM) and to establish a scoring system in guiding treatment modalities.

Methods:

An interventional, prospective study was done on 82 eyes of post-COVID-19 ROCM from May 2021 to July 2021. A comprehensive multi-departmental evaluation along with detailed ophthalmic examination, laboratory investigations, and radiological examination was done. Scoring points were given to each symptom, sign, and radiological features of orbit and the total score was taken. Based on these scores, severity of disease was grouped into A, B, and C corresponding to mild, moderate, and severe orbital ROCM. One milliliter of reconstituted liposomal amphotericin B was given to all patients every alternate day as three doses. Efficacy of these injections was assessed in all groups, even though other treatment modalities like orbital debridement and exenteration were considered for moderate and severe cases. Patients were followed up for a period of 8 weeks.

Results:

Out of 82 eyes, symptomatic improvement was seen in a major proportion (72%) of patients. A statistically significant improvement in scores was noted in group A (93% improved) with a P value of 0.002, while 68.4% showed improvement in group B (P-value- 0.0001). Group C with severe disease showed minimal improvement in post-injection scores of 41% (P-value 0.086), necessitating surgical intervention. No serious adverse effect of the drug or procedure was noted.

Conclusion:

Significant improvement in scores of groups A and B highlights TRAMB as an effective and safe treatment modality in mild to moderate ROCM. It is an effective adjunct in severe cases, along with other interventions. Also, the scoring system helps in assessing the severity and guiding in management strategies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Orbital Diseases / Eye Infections, Fungal / COVID-19 / Mucormycosis Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Indian J Ophthalmol Year: 2022 Document Type: Article Affiliation country: Ijo.IJO_2356_21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Orbital Diseases / Eye Infections, Fungal / COVID-19 / Mucormycosis Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Indian J Ophthalmol Year: 2022 Document Type: Article Affiliation country: Ijo.IJO_2356_21